Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Early IgG / IgA response in hospitalized COVID-19 patients is associated with a less severe disease

Giorgio Fedele¹,²,¹, Gianluca Russo,²,¹ Ilaria Schiavoni,² Pasqualina Leone,² Eleonora Olivetta,² Valentina Perri,² Maria Antonella Zingaropoli,² Maria Rosa Giardi,² Patrizia Pasculli,² Claudio Maria Mastroianni,² Paola Stefanelli²

¹ Department of Infectious Diseases, Istituto Superiore di Sanità, Italy
² National Centre for Global Health, Istituto Superiore di Sanità, Italy
³ Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy

ABSTRACT

We determined the kinetics of anti–SARS-CoV-2 antibody response in fifteen hospitalized COVID-19 patients. Patients were divided into mild/moderate (mild, n = 1; moderate, n = 4) or severe (n = 10) and virus-specific anti–Nucleocapsid IgM, anti–Spike IgG and anti–Spike IgA were measured in serial serum samples collected 0 to 15 days after hospital admission. Surrogate neutralization assays were performed by testing inhibition of ACE-2 binding to Spike. In 3 patients (2 severe and 1 moderate case), serum antibodies and T-cell memory were monitored 6 months after baseline. Although IgM response tended to appear first, patients affected by less severe disease were more prone to an early IgG/IgA response. Neutralization of Spike binding to ACE2 correlated with anti–Spike IgG and IgA. IgG and IgA antibody response persisted at the 6 months follow-up. A recall T-cell response to the Spike antigen was observed in 2 out of 3 patients, not related to disease severity.

© 2021 Elsevier Inc. All rights reserved.

1. Introduction

The immune response against SARS-CoV-2 remains unclear and many caveats in its knowledge are still present. A correlation of clinical severity with high titres of SARS-CoV-2 antibodies, mainly immunoglobulin (Ig)G, was shown (Zhao et al., 2020; Long et al., 2020; Ma et al., 2020), and the importance of neutralizing humoral immunity on disease progression has been shown (Garcia-Beltran et al., 2021). Fewer studies assessed serum SARS-CoV-2 IgA; this Ig subclass becomes detectable 4 to 6 days after symptom onset with a higher and more persistent serum level than IgM (Padoan et al., 2020; Yu et al., 2020). IgA levels seem significantly higher in severe than in mild/moderate SARS-CoV-2 infections (Yu et al., 2020; Bartsch et al., 2021).

Early antibody responses appear to be correlated with disease outcome (Atyeo et al., 2020). Timing of IgM and IgG seroconversion is controversial, with serum IgM appearing before IgG or synchronously (Zhao et al., 2019; Xiang et al., 2020), or even later (To et al., 2020; Zhang et al., 2020). There is growing evidence of pre-existing humoral and T-cell immunity caused by exposure to common cold coronaviruses (Ng et al., 2020; Sette and Crotty, 2020). Immunity to SARS-CoV-2 is also related to T-cell responses (McMahan et al., 2021). Patients who resolve infection have been shown to generate virus–specific T–cell responses (Sekine et al., 2020; Weiskopf et al., 2020). It has been proposed that SARS-CoV-2 induces multifunctional memory T cells which play a role in preventing recurrent episodes of severe SARS-CoV-2 infections (Sekine et al., 2020; Grifoni et al., 2020).

The objective of the study was the characterization of the serologic response to SARS-CoV-2 in patients hospitalized with confirmed SARS-CoV-2 infection. We aimed at comparing the kinetics of IgM, IgG, IgA, and virus neutralization activity in a group of patients affected by mild/moderate or severe SARS-CoV-2 infection. Six months after baseline, SARS-CoV-2 specific antibodies, and T-cell responses were measured in a smaller number of individuals.

2. Material and methods

2.1. Clinical sample

Fifteen patients hospitalized with confirmed COVID-19 at the Infectious Diseases division of Policlinico Umberto I Hospital, Rome, Italy, were included in the study (Table 1). The study was approved by local Ethic Committee and all participants have signed an informed consent. At the hospital admission all patients were affected by COVID-19 related pneumonia and, according to the PaO2/FiO2 ratio...
(partial oxygen pressure/oxygen flow), 10 patients were classified as having a severe disease (PaO2/FiO2 < 250), 4 having a moderate disease (PaO2/FiO2 > 250) in need of oxygen supply, and 1 having mild disease (PaO2/FiO2 > 250, no need of oxygen supply). Patients were re-tested for SARS-CoV-2 RNA 6 days after hospital admission and then every 2 days, until a negative nasopharyngeal (NP) swab result was obtained.

2.2. Serology

Serum samples were available at 3 different time-points: at hospital admission (T0), 5 to 10 days (T1), and 11 to 15 days (T2) after hospital admission. Immediately after collection, sera were shipped to the Department of Infectious Diseases, Istituto Superiore di Sanità (ISS); 0.5 mL aliquots were prepared and stored at -80°C. Serology testing was performed at ISS by personnel blinded to specimen classiﬁcation within 1 month from serum collection.

ELISA assays were used to measure Anti-Nucleocapsid IgM (Dia-Pro diagnostics Bioprobes, Sesto San Giovanni (MI), Italy), anti-Spike IgG and anti-Spike IgA (both from Euroimmun, Lübeck, Germany), according to manufacturers’ instructions. A surrogate neutralization assay (GenScript, Leiden, The Netherlands) was used to detect the virus neutralizing ability of patients’ sera. The assay detects and measures neutralizing antibodies blocking the Spike RBD-ACE2 interaction in vitro and was used according to manufacturer’s instructions.

2.3. T-cell response

Additional blood samples from patients #4, #11 and #15 were collected 6 months after hospital discharge and humoral and T-cell immune responses to SARS-CoV-2 assessed. Since the second wave of Covid-19 cases hit the Policlinico Umberto I hospital at the end of September 2020, it was not possible to include in the 6-month follow-up study other patients, due to safety concerns. Virus-speciﬁc T-cell responses were measured by stimulating patients’ peripheral blood mononuclear cells (PBMCs) with overlapping peptides covering the immunodominant sequence domains of the Spike protein (Milenyi, Bergisch Gladbach, Germany). After overnight stimulation, cells were incubated with Live/Dead fixable violet dead cell stain kit used to exclude dead cells from the analyses (Thermo Fisher Scientiﬁc, Wallingford, MA). Cells were then ﬁxed in paraformaldehyde 2%, permeabilized using a solution containing saponin 0.5% and stained with a predetermined optimal concentration ofﬂuorochrome-conjugated Abs: anti-CD3-Horizon-BV510, anti-IL-2-FITC, anti-3NFε PE-Cy7 (all from BD Biosciences, Franklin Lakes, NJ), anti-IL-4-APC, anti-IL-7-APC, anti-IFN-γ-PerCP-Cy5.5 (both from Biolegend, San Diego, CA), anti-CD8-PE (ebiSciences, Thermo Fisher Scientiﬁc).

3. Results

3.1. Clinical sample

Fifteen patients were included in the study (Table 1). Patients with mild/moderate SARS-CoV-2 infection had a lower mean age (59.0 vs 66.8; \( P=0.27 \)) and higher median Ct values of PCR from NP samples (gene E: 32.10 vs 25.35, \( P=0.05 \); gene S: 31.00 vs 24.65, \( P=0.058 \)) than those with severe infection. As expected, severely ill patients required more days for a negative result of NP swab (median 16.0 vs 13.0; \( P=0.29 \)).

3.2. Anti-SARS-CoV-2 IgM, IgG, IgA antibody responses

Serum samples were collected at hospital admission (T0), 5 to 10 days (T1), and 11 to 15 days (T2) after hospital admission. At T0, IgM specific for the viral nucleocapsid protein were above the positivity threshold in 9 patients (60.0%). At T1, a positive IgM response was measured in 12 patients (80.0%); at T2, 13 patients (86.7%) had a positive IgM response. The IgM response showed a slightly higher median value among severely affected patients at T1 and lower at T2 (Fig. 1).

Anti-Spike IgG at T0 were above the positivity threshold in 5 patients (13.3%). At T1 a positive IgG response was measured in 13 patients (86.7%); at T2 14 patients (93.3%) had a positive IgG response. When patients were classified according to disease severity, we found that at T0 the median IgG response was higher in mild/moderate patients, although this difference was not statistically significant. IgG levels were higher among severely affected patients at T2 (Fig. 1).

Anti-Spike IgA at T0 were above the positivity threshold in 5 patients (13.3%). At T1 a positive IgA response was measured in 13 patients (86.7%); at T2 14 patients (93.3%) had a positive IgA response. When patients were classified according to disease severity, we found that at T0 the median IgA response was higher in mild/moderate patients, although this difference was not statistically significant. IgA levels were higher among severely affected patients at T2 (Fig. 1).

3.3. SARS-CoV-2 neutralization correlates with IgG and IgA serum levels in laboratory-confirmed COVID-19 patients

At hospital admission Spike RBD-ACE2 neutralization activity was measured in 13 patients (86.7%). At T1 and T2 a

| Patient Nr. | Sex | Age, years | Comorbidities | Days from symptoms onset to hospital admission | Clinical severity | Oxygen supply during hospital stay | CT value E gene | CT value S gene | Days to SARS-CoV-2 negative NP swab | Length of hospital stay, days |
|-------------|-----|------------|---------------|---------------------------------------------|------------------|-----------------------------------|----------------|----------------|-----------------------------------|-------------------------------|
| 1           | F   | 64         | AI, DM        | 10                                          | Mild             | None                              | 32.9           | 32.2           | 9                                 | 19                            |
| 2           | M   | 48         | NHL           | 2                                           | Moderate         | VM                                | 29.8           | 28.9           | 14                                | 16                            |
| 3           | M   | 83         | AI, IHD       | 7                                           | Moderate         | VM                                | 28.2           | 27.1           | 17                                | 35                            |
| 4           | M   | 42         | DM            | 6                                           | Moderate         | VM                                | 32.6           | 34.2           | 13                                | 19                            |
| 5           | M   | 58         | AI            | 13                                          | Moderate         | VM                                | 32.1           | 31.0           | 12                                | 19                            |
| 6           | M   | 62         | None          | 6                                           | Severe           | HFNC/CPAP                        | 22.2           | 21.2           | NA                                | 27                            |
| 7           | M   | 78         | Lung cancer   | 1                                           | Severe           | HFNC/CPAP                        | 14.9           | 14.8           | NA                                | 28                            |
| 8           | M   | 64         | None          | 10                                          | Severe           | HFNC/CPAP                        | 23.8           | 23.2           | 25                                | 28                            |
| 9           | F   | 60         | AI            | 4                                           | Severe           | HFNC/CPAP                        | 20.3           | 19.3           | 17                                | 21                            |
| 10          | M   | 69         | None          | 3                                           | Severe           | HFNC/CPAP                        | 31.0           | 32.0           | 12                                | 14                            |
| 11          | M   | 52         | None          | 3                                           | Severe           | HFNC/CPAP                        | 23.6           | 22.9           | 25                                | 30                            |
| 12          | M   | 78         | AI            | 8                                           | Severe           | HFNC/CPAP                        | 35.7           | 32.2           | 15                                | 47                            |
| 13          | M   | 66         | None          | 5                                           | Severe           | HFNC/CPAP                        | 27.4           | 28.1           | 11                                | 21                            |
| 14          | M   | 76         | AI, COPD, HT  | 12                                          | Severe           | HFNC/CPAP                        | 26.9           | 26.1           | 25                                | 38                            |
| 15          | F   | 63         | None          | 7                                           | Severe           | HFNC/CPAP                        | 31.0           | 30.2           | 12                                | 19                            |
neutralizing response was measured in all the patients. Patients with mild/moderate disease presented higher neutralizing antibody levels at hospital admission as compared to severe patients, although this was not statistically significant (Figure 1).

A statistically significant positive correlation of in vitro neutralization of Spike RBD-ACE2 binding with IgG and IgA serum levels at all the time-points was found, whereas no correlation was evident between anti-Nucleocapsid IgM and Spike RBD-ACE2 neutralizing activity (Fig. 2).

Fig. 1. SARS-CoV-2 specific antibody response in mild/moderate and severe COVID-19 patients. Serologic anti-Nucleocapsid IgM, anti-Spike IgG, and anti-Spike IgA antibodies were tested by enzyme-linked immunosorbent assay. Sera neutralization activity was assessed by surrogate virus neutralization test based on antibody-mediated blockage of ACE2-Spike protein-protein interaction. Solid horizontal lines represent Mean. Dotted lines represent positivity thresholds. T0: hospital admission; T1: 5 to 10 days after hospital admission; T2: 11 to 15 days after hospital admission; S/Co: Signal to Cut-off (S/Co) ratio.
3.4. Persistence of anti-SARS-CoV2 immunity 6 months after the infection

A 6-month follow-up analysis was performed on 3 out of 15 patients. We did not observe any decline in anti-Spike IgG levels (T2 mean ± SD: 6.53 ± 0.27; 6-month mean ± SD: 6.21 ± 0.9). Anti-Spike IgA levels declined but were still above the positivity threshold (T2 mean ± SD: 11.70 ± 0.56; 6-month mean ± SD: 4.13 ± 2.16). Sera retained surrogate neutralization activity (data not shown). Two patients (1 moderate and 1 severe case) were able to mount a virus-specific T-cell response, marked by the production of TNF-α and IFN-γ by CD4 and CD8 T cells (Fig. 3), while 1 patient was unresponsive. Profiles of T-cell response were rather different. A higher frequency of cytokine positive CD4+ versus CD8+ T cells (0.91% vs 0.56%) was found in patient #10 (moderate), while in patient #15 (severe) this ratio was inverted (0.78% vs 0.96%). The proportion of CD4 and CD8 cells producing 1, 2 or 3 cytokines was also different in the 2 responsive patients.

4. Discussion

The correlation of antibody responses to SARS-CoV-2 with COVID-19 disease severity is still unclear. Our data suggest that individuals with an earlier appearance of virus-specific IgG and IgA potentially have a better outcome. In patients with a mild/moderate disease, IgG responses tended to occur simultaneously with IgM or even slightly earlier, while in patients with severe disease IgG and IgA were produced later during the course of the disease. Both IgG and IgA levels were correlated to serum neutralizing activity.

Our observations agree with a recent study by Carsetti and co-workers (2020) who found that IgA and IgG produced relatively late in the course of the infection characterize severe disease (Carsetti et al, 2020). Moreover, it has been shown that patients with more severe illness display higher antibody titers than those with milder disease (Long et al, 2020; Röltgen et al, 2020).

The presence of anti-SARS-CoV-2 IgG and IgA at T0 in mild/moderate patients suggests that some pre-existing immunity to the 4 endemic coronaviruses causing common cold in humans (HCoV-229E, -NL63, -OC43, and -HKU1) may play a role in counteracting the infection. These findings are supported by a recent study showing that COVID-19 disease appears less severe in patients with endemic coronavirus infection (Sagar et al, 2021).

5. Limitations

Before drawing conclusions, limitations of the study should be mentioned. The number of patients enrolled is small and probably not sufficient for making strong conclusions. Only 3 patients were used in the cellular immunity studies at 6 months. Although incomplete and preliminary, the 6-month follow-up showed the persistence of serologic response in 3 patients. Data on T-cell response
suggested the possibility of differential responses that could reflect asymptomatic exposure.

6. Conclusion

In conclusion, our data confirm the notion that an early IgG/IgA response focused on the Spike protein may help to counteract the viral infection, leading to a milder course of the disease. Further studies are required to investigate more in depth the duration and patterns of T-cell memory responses.

Acknowledgments

The authors wish to thank the ISS working group on COVID-19: Stefano Fiore, Concetta Fabiani, Eleonora Benedetti, Angela Di Martino, Laura Calzoletti, Marzia Facchini, Giuseppina Di Mario, Giulietta Venturi, Claudia Fortuna, Antonello Amendola, Giulia Marsili.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Declaration of competing interest

The authors have nothing to disclose.

Authors’ contributions

Giorgio Fedele: conceptualization, data curation, writing-original draft preparation and revised version; Gianluca Russo: conceptualization, data curation, writing-original draft preparation and revised version; Ilaria Schiavoni: investigation and Writing-Reviewing; Pasqualina Leone: investigation; Eleonora Olivetta: investigation; Valentina Perri, Maria Antonella Zingaropoli, Maria Rosa Ciardi and Patrizia Pasculli: resources; Claudio Maria Mastroianni: supervision; Paola Stefanelli: conceptualization and supervision.

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.diagmicrobio.2021.115539.

References

Atyeo C, Fischinger S, Zohar T, Slein MD, Burke J, Loos C, et al. Distinct early serological signatures track with SARS-CoV-2 survival. Immunity 2020 15;53(3):524–532.e4.
Bartsch YC, Wang C, Zohar T, Fischinger S, Attyeo C, Burke JS, et al. Humoral signatures of protective and pathological SARS-CoV-2 infection in children. Nat Med 2021.

Carsetti R, Zaffina S, Piano Mortari E, Terreri S, Corrente F, Capponi C, et al. Different innate and adaptive immune responses to sars-cov-2 infection of asymptomatic, mild, and severe cases. Front Immunol 2020;11:610300.

Garcia-Beltran WF, Lam EC, Astudillo MG, Yang D, Miller TE, Feldman J, et al. COVID-19 neutralizing antibodies predict disease severity and survival. Cell 2021;184(2):476–488.e11.

Grifoni A, Weiskopf D, Ramirez SL, Mateus J, Dan JM, Rydzymski Moderbacher C, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 2020;181(7):1489–1501.e15.

Long QX, Tang XJ, Shi QJ, Li Q, Deng HJ, Yuan J, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med 2020;26(8):1200–4.

Ma H, Zeng W, He H, Zhao D, Jiang D, Zhou P, et al. Serum IgA, IgM, and IgG responses in COVID-19. Cell Mol Immunol 2020;17(7):773–5.

McMahen K, Yu J, Mercado NB, Loos C, Tostanoski LJ, Chandrashekara A, et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature 2021;590(7847):630–4.

Ng Kw, Faulkner N, Cornish GH, Rosa A, Harvey R, Hussain S, et al. Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. Science 2020;370(6522):1339–43.

Padoan A, Sircacovelli L, Bassi D, Negrini D, Zuin S, Cosma C, et al. IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: a longitudinal study. Clin Chim Acta 2020;507:164–6.

Røtgen K, Powell AE, Wirz OF, Stevens BA, Hogan CA, Najeeb J, et al. Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome. Sci Immunol 2020;5(54):eabe0240.

Sagar M, Reifler K, Rossi M, Miller NS, Sinha P, White LF, et al. Recent endemic coronavirus infection is associated with less-severe COVID-19. J Clin Invest 2021;131(1):e143380.

Sekine T, Perez-Putti A, Rivera-Ballesteros O, Stralin K, Gorin JB, Olsson A, et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell 2020;183(1):158–168.e14.

Sette A, Crotty S. Pre-existing immunity to SARS-CoV-2: the knowns and unknowns. Nat Rev Immunol 2020;20(8):457–8.

To KKW, Tsang OTY, Leung WS, Tam AR, Wu TC, Lung DC, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis 2020;20(5):565–74.

Weiskopf D, Schmitz KS, Raadsen MP, Grifoni A, Okba NMA, Endeman H, et al. Phenotype of SARS-CoV-2-specific T-cells in COVID-19 patients with acute respiratory distress syndrome. Sci Immunol 2020;5(48):eaab2071.

Xiang F, Wang X, He X, Peng Z, Yang B, Zhang J, et al. Antibody detection and dynamic characteristics in patients with COVID-19. Clin Infect Dis 2020;71(8):1930–4.

Yu HQ, Sun BQ, Fang ZF, Zhao JC, Liu XY, Li YM, et al. Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients. Eur Respir J 2020;56(2):2001526.

Zhang W, Du RH, Li B, Zheng XS, Yang XL, Hu B, et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerg Microbes Infect 2020;9(1):386–9.

Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody response to SARS-CoV-2 in patients of novel coronavirus diseases 2019. Clin Infect Dis 2020;71(16):2027–34.